Achira

Achira is at the forefront of transforming drug discovery by developing atomistic foundation simulation models. The company integrates geometric deep learning, physics, quantum chemistry, and statistical mechanics to create advanced potentials and generative models. This approach aims to overcome the limitations of traditional biomolecular simulations and pure machine learning models, which are often constrained by data scarcity and acquisition costs. Achira's innovative models generate large, accurate synthetic datasets, free from experimental artifacts, enabling a shift towards a true inverse design problem in drug discovery. The company serves pharmaceutical and biotech clients, operating in the drug discovery market. Achira's business model focuses on leveraging its proprietary simulation technology to provide solutions that enhance the efficiency and effectiveness of therapeutic compound discovery. Revenue is generated through partnerships, licensing agreements, and collaborations with industry stakeholders. Achira has secured $33 million in funding from investors including Dimension, Amplify, NVIDIA, and Compound, underscoring the market's confidence in its potential to revolutionize drug discovery.

Keywords: drug discovery, simulation models, geometric deep learning, quantum chemistry, biomolecular applications, synthetic datasets, inverse design, pharmaceutical, biotech, funding.